During lactating-cow mastitis therapy, the intramammary infusion product is assembled as an aseptically filled, single-dose suspension of ceftiofur hydrochloride equivalent to 125 mg ceftiofur per 10 mL syringe. The API is micronized by air-jet milling, and the particle size distribution is verified by laser diffraction according to ISO 13320:2020; the target distribution is fixed in the registered specification because settling rate scales with the square of particle diameter and because oversized crystals reduce dose uniformity during high-speed syringe filling. The vehicle consists of a sterilized long-acting oil or gel base; its viscosity is measured at 25 °C using a cone-and-plate rheometer, and the shear-thinning profile is controlled to permit complete evacuation through the intramammary cannula while retaining the drug in the udder sinus after infusion. Aseptic filling takes place on a single-dose syringe line with fill weight verification to ±1.0%; plunger rod insertion force is monitored because excessive insertion force damages the rubber tip and allows air entrapment. Container closure integrity is verified by vacuum decay according to USP <1207>. Each batch is tested for sterility by membrane filtration according to USP <71> and for bacterial endotoxins by the limulus amebocyte lysate method according to USP <85>. The approved label directs once-daily infusion into each infected quarter for a period of 2 to 8 consecutive days based on clinical response; pathogen susceptibility is interpreted using CLSI VET01S breakpoints for Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, and coagulase-negative staphylococci. Milk residue depletion is governed by the ceftiofur tolerance in 21 CFR 556.113, which establishes 0.1 ppm as the target level in milk; milking discard periods are product-specific and must be validated by residue depletion studies rather than assumed from the dose. In manufacturing, the most frequent batch rejection arises not from chemical assay but from visible particle agglomeration after accelerated aging at 40 °C/75% RH; agglomeration is addressed by controlling residual moisture in the API below the registered limit and by inert-gas blanketing of the vehicle during compounding.

Dry-cow intramammary infusion requires a slower release profile than lactating-cow therapy

Because the dry period lasts 45 to 60 days, the dry-cow product is formulated with a higher ceftiofur hydrochloride loading of 500 mg per 10 mL syringe to provide extended residence in the involuting mammary gland. Unlike the lactating formulation, the dry-cow suspension is designed for a single administration at dry-off; the vehicle viscosity and particle size distribution are shifted to reduce drainage from the teat canal and to maintain contact with keratin plugs and mucosal surfaces over a period of weeks. The API is dispersed in a sterile oil-based vehicle under high-shear rotor-stator mixing at controlled vacuum to prevent air entrainment. In-process controls include particle size analysis by laser diffraction, viscosity measurement at 25 °C, and syringe fill weight. Sterility is validated by membrane filtration per USP <71>; endotoxin limits are determined per USP <85>. The formulation is evaluated for physical stability at 25 °C/60% RH over the assigned shelf life, with periodic resuspendability testing to confirm that settled solids redisperse within the specified number of manual inversions. A production line bottleneck occurs when the suspension is not fully degassed before filling; microscopic air bubbles accumulate in the syringe tip and displace dose volume during high-speed filling. Operators therefore monitor vacuum level and fill nozzle back-pressure. From a residue perspective, the dry-cow dose must be cleared before the next lactation; residue depletion studies under 21 CFR 556.113 are product-specific, and published product labels provide separate pre-slaughter and milk discard criteria for dry-cow formulations. Clinical use is restricted to cows at dry-off; the product is not intended for lactating-cow therapy because the higher dose and prolonged retention produce different milk residue kinetics in the lactating gland.When sterile ceftiofur sodium powder is processed for reconstitution, the aseptic train begins with the sterile API received from a validated crystallization and drying train. The sodium salt is dissolved in Water for Injection, sterile-filtered through a 0.22 µm membrane, and transferred to a lyophilizer where chamber pressure and shelf temperature are programmed to remove water without exceeding the beta-lactam degradation boundary. Residual moisture is determined by Karl Fischer titration according to USP <921> Method Ia; excursions above the registered limit, commonly 1.0% w/w, accelerate solid-state hydrolysis and produce caking that prolongs reconstitution time beyond the label acceptance value. The dry powder is filled into Type I borosilicate glass vials conforming to ISO 8362-1:2018, stoppered with chlorobutyl elastomeric closures under nitrogen, and sealed with aluminum caps. Each reconstituted vial is intended to deliver 50 mg/mL of ceftiofur equivalents after addition of sterile diluent; the diluent volume is verified by gravimetric check on the packaging line. Subvisible particulate matter is controlled by light obscuration according to USP <788>; sterility testing follows USP <71>, and bacterial endotoxin testing follows USP <85>. The reconstituted solution is used for intramuscular or subcutaneous injection in cattle and swine; injection volume, needle gauge, and site rotation are determined by the approved product label. In commercial practice, the principal formulation failure mode is residual moisture variance across the lyophilizer deck, which appears as intra-batch variation in reconstitution time and occasional stopper pop-back during drying. Load thermocouple mapping and programmed secondary drying at low shelf temperature are used to reduce this variance. The solution should not be mixed with aminoglycoside antibiotics in the same syringe because in vitro inactivation of the aminoglycoside by beta-lactam ring opening has been reported; separate injection sites and times are required.

What rheological constraints govern a 200 mg/mL crystalline free acid suspension?

Designed for extended release after subcutaneous injection, the 200 mg/mL ceftiofur crystalline free acid suspension is a ready-to-use sterile parenteral whose critical formulation variable is particle size. The crystalline free acid exhibits low aqueous solubility, and the absorption rate after injection is controlled by the surface area of suspended drug particles; reducing the median particle size below the registered distribution accelerates dissolution but can increase injection-site irritation, while oversized particles reduce syringeability and may settle irreversibly. Particle size distribution is measured by laser diffraction according to ISO 13320:2020, with the specification expressed as Dv10, Dv50, and Dv90. The vehicle is a sterile non-aqueous oil system; its viscosity is characterized on a cone-and-plate rheometer at 20 °C and 25 °C, and the product is filled through a low-shear piston pump to avoid particle fracture. Syringeability is evaluated using a 16-gauge needle at a defined extension rate and temperature; the acceptance criterion is the force required to express a full dose. Sterility and endotoxin limits follow USP <71> and USP <85>. Because the suspension is non-aqueous, water activity is monitored to prevent hydrolysis during shelf life; the product is packaged in glass vials with nitrogen overlay. A recurring production issue is crystal bridging in the filling nozzle when the suspension is held too long without recirculation; gentle agitation and temperature control at 18 °C to 22 °C prevent this failure. In the field, the product is administered subcutaneously in the middle third of the ear in cattle and in the post-auricular region in swine according to approved labels; animal-specific withdrawal periods are established under 21 CFR 556.113 and printed in the package insert. This dosage form cannot be diluted with water for injection or mixed with aqueous diluents because the non-aqueous vehicle and particle size distribution define the release profile.For ready-to-use ceftiofur hydrochloride injection at 50 mg/mL, the formulation is an aqueous suspension intended for intramuscular or subcutaneous administration in cattle, sheep, goats, and swine. The API is micronized and suspended in an aqueous vehicle containing wetting and suspending agents; the wetting agent reduces interfacial tension and improves particle dispersion, while the suspending agent increases viscosity to slow sedimentation. Resuspendability is tested by controlled inversion and by measuring the sedimentation volume after storage; a low sedimentation volume indicates caking and may lead to dose non-uniformity. The product is filled aseptically into multi-dose glass vials, and the closure is a chlorobutyl elastomer that must not release leachable compounds affecting the pH of the suspension. In-process controls include pH measurement, osmolality, viscosity, and particle size distribution. Sterility is verified by USP <71>, bacterial endotoxins by USP <85>, and subvisible particulate matter by USP <788>. Production-scale equipment for this suspension typically includes a jacketed compounding vessel with bottom-mounted rotor-stator homogenizer, a recirculation loop, and a gentle agitation system to avoid particle fracture. The most common line failure is foaming during homogenization; foam entrains air, increases oxidation, and reduces fill accuracy. Vacuum homogenization and slow impeller speed during transfer are used to control foam. The product is not suitable for intramammary infusion or intravenous injection; the particle size and vehicle are designed for deep intramuscular or subcutaneous deposition. Animal-specific dosing, injection volume, and withdrawal periods are established in the approved label under 21 CFR 556.113; published data for minor species may be limited, and use in animals other than those listed on the label must be justified by a veterinarian under applicable regulatory constraints.

Dosage form	API form	Representative concentration	Critical control point	Test method	Key limitation
Lactating-cow intramammary suspension	Ceftiofur hydrochloride	125 mg/10 mL	Particle size and syringe fill	ISO 13320:2020; USP <71>	Milk discard and pathogen susceptibility
Dry-cow intramammary suspension	Ceftiofur hydrochloride	500 mg/10 mL	Vehicle viscosity and sterility	USP <71>; USP <85>	Prolonged retention in involuting gland
Injectable sterile powder for reconstitution	Ceftiofur sodium	50 mg/mL after reconstitution	Residual moisture and reconstitution time	USP <921>; USP <788>	Shelf-life degradation if moisture exceeds limit
Ready-to-use parenteral suspension	Ceftiofur hydrochloride	50 mg/mL	Resuspendability and particle size distribution	USP <788>; ISO 13320:2020	Not suitable for intravenous or intramammary use
Extended-release crystalline free acid suspension	Ceftiofur crystalline free acid	200 mg/mL	Particle size and non-aqueous vehicle	ISO 13320:2020; USP <71>	Cannot be diluted with aqueous diluents
Oral tablet or capsule	Ceftiofur hydrochloride	Not approved	Gastric pH instability	USP <711> would not predict absorption	No residue depletion data; cephalosporin restrictions apply

When oral tablet or capsule forms are evaluated, the beta-lactam stability boundary defines the feasibility window

In monogastric species, gastric pH below 3.5 initiates ring opening within minutes, and the resulting desfuroylceftiofur derivatives do not possess the same antimicrobial activity; oral dosage forms of ceftiofur for tablets or capsules therefore face a fundamental barrier. Published oral bioavailability data for ceftiofur in target species are limited; no approved oral ceftiofur tablet, capsule, or oral suspension exists for food-producing animals. If a compounded tablet is contemplated, dry granulation is the only viable processing route because wet granulation with aqueous binder accelerates hydrolysis and reduces assay. The dry granulation blend would require a protective polymer coat, and even then dissolution testing by USP <711> would not predict systemic absorption because the drug must survive gastric transit. Capsules present the same limitation; the capsule shell dissolves in gastric fluid and exposes the API to acid. For food-producing species, extralabel use of cephalosporins is restricted under 21 CFR 530.41, and a tablet or capsule form would not have a validated residue depletion profile under 21 CFR 556.113. Oral tablet and capsule development is therefore not supported by current veterinary regulatory data. The formulation effort is better directed to injectable and intramammary routes, where ceftiofur reaches therapeutic plasma or mammary tissue concentrations after parenteral or local administration.Across medicated water and feed premix evaluations, two independent barriers dominate. The first is chemical: ceftiofur hydrochloride and ceftiofur sodium are hydrolytically unstable in aqueous solution, and the rate of beta-lactam ring opening accelerates as water activity, temperature, and pH deviate from neutral. Medicated water lines operate at variable pH, often between 6.5 and 8.0 depending on source water alkalinity and disinfectant residuals; chlorine and chloramine can further degrade the molecule. A dry powder or granule premix would reduce water contact during storage, but once reconstituted in drinking water the drug must be consumed quickly, and stability in the target water matrix must be demonstrated. The second barrier is regulatory: ceftiofur is not approved as a feed or water medication in food-producing species, and no validated oral residue depletion data exist for this route. Any water-soluble powder or premix would require a full residue depletion study under 21 CFR 556.113 and would likely fall under the cephalosporin extralabel restrictions in 21 CFR 530.41. Granulation itself presents a processing problem: wet granulation promotes hydrolysis, and dry granulation of a beta-lactam requires careful control of compaction force to avoid amorphization. Milling of granules to a premix particle size also generates heat and local amorphous domains that are more reactive. These constraints explain why commercial ceftiofur products remain parenteral or intramammary, and why powder or granule premix development is not reported in approved product literature. Published data for this specific configuration is limited.

Aqueous reconstituted solution stability and pH-dependent degradation kinetics

Below pH 4.0 and above pH 8.0, beta-lactam ring opening accelerates and active ceftiofur concentration declines; the stability of reconstituted ceftiofur sodium solutions is governed by pH-dependent hydrolysis, temperature, buffer concentration, and trace metal ions. The drug is most stable in a narrow physicochemical window near neutral pH. Solution stability studies typically employ pH-stat kinetic measurements at controlled temperature, with sampling at defined intervals and high-performance liquid chromatography assay to quantify intact ceftiofur and desfuroylceftiofur-related degradation products. Arrhenius treatment of degradation rate constants at 25 °C, 30 °C, and 40 °C provides the shelf-life prediction for the reconstituted product. In practice, reconstituted vials are stored at 2 °C to 8 °C and used within the period stated in the approved label; repeated needle punctures of the rubber stopper increase oxygen ingress and microbial contamination risk. Phosphate and carbonate buffers may be used in analytical stability protocols, but the reconstitution diluent for clinical use is usually Sterile Water for Injection to avoid electrolyte incompatibilities. Subvisible particle formation can occur after reconstitution if the solution is vigorously shaken; gentle swirling is specified to minimize mechanical stress and particle generation. Any visible precipitate, turbidity, or color change after reconstitution indicates degradation or contamination and requires immediate discard. The compatibility of reconstituted ceftiofur with other injectable solutions is not universal; dextrose-containing intravenous fluids and solutions of aminoglycosides should not be mixed with the reconstituted product because of pH differences and chemical inactivation.